tiprankstipranks
Trending News
More News >

CymaBay downgraded to Market Perform from Outperform at Leerink

Leerink downgraded CymaBay Therapeutics to Market Perform from Outperform with a $32.50 price target after Gilead Sciences (GILD) announced an agreement to acquire Cymabay for $32.50 per share in cash.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See Insiders’ Hot Stocks on TipRanks >>

Read More on CBAY:

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue